Beirne Wealth Consulting Services, LLC Novavax Inc Transaction History

Beirne Wealth Consulting Services, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$36.28 - $75.29 $114,282 - $237,163	-3,150 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$69.73 - $142.9 $219,649 - $450,135	3,150 New	3,150 $232,000
Q4 2021 Feb 03, 2022	SELL	$134.56 - $217.97 $161,472 - $261,564	-1,200 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$177.8 - $270.58 $124,460 - $189,406	-700 Reduced 36.84%	1,200 $249,000
Q2 2021 Aug 10, 2021	BUY	$121.0 - $257.67 $84,700 - $180,369	700 Added 58.33%	1,900 $404,000
Q1 2021 May 17, 2021	BUY	$112.98 - $319.93 $135,576 - $383,916	1,200 New	1,200 $218,000
Q3 2020 Nov 05, 2020	SELL	$79.44 - $178.51 $1.77 Million - $3.97 Million	-22,250 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$13.86 - $83.61 $523,215 - $3.16 Million	-37,750 Reduced 62.92%	22,250 $1.86 Million
Q1 2020 Apr 28, 2020	BUY	$3.93 - $16.0 $44,212 - $180,000	11,250 Added 23.08%	60,000 $815,000
Q4 2019 Jan 14, 2020	BUY	$3.69 - $5.22 $8,302 - $11,745	2,250 Added 4.84%	48,750 $194,000
Q3 2019 Nov 07, 2019	BUY	$4.02 - $7.84 $186,929 - $364,560	46,500 New	46,500 $233,000

284

84.8M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $731M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Beirne Wealth Consulting Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Beirne Wealth Consulting Services, LLC with notifications on news.